Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR Therapeutics, Neon Therapeutics Enter Research Collaboration

NEW YORK (GenomeWeb) – CRISPR Therapeutics and Neon Therapeutics said today that they have entered a research collaboration to explore using a combination of each company's proprietary technologies to develop novel T cell therapies.

Headquartered in Basel, Switzerland, CRISPR Therapeutics is a gene-editing company focused on developing gene-based medicines for serious diseases using a proprietary CRISPR/Cas9 gene-editing platform.

Neon Therapeutics is an immune-oncology firm developing novel cancer drugs that leverage neoantigen biology, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. The company's current lead program is a personalized neoantigen vaccine now in multiple clinical trials.

"We look forward to applying our proprietary CRISPR/Cas9 technologies in a variety of ways to generate potent T cell therapies directed against neoantigens," CRISPR Therapeutics President Samarth Kulkarni said in a statement.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.